FDA restricts Johnson & Johnson COVID vaccine due to blood clot risk

A dose of the Johnson & Johnson COVID-19 vaccine.
(Image credit: Michael Ciaglo/Getty Images)

The Food and Drug Administration on Thursday limited who can receive the Johnson & Johnson COVID-19 vaccine, citing concerns over a rare and serious blood clotting condition.

The vaccine is under an emergency use authorization, for adults 18 and older, and the FDA said in a statement that it should now only be given to people who can't or won't get any other vaccine. The agency said it came to this determination after conducting "an updated analysis, evaluation, and investigation" of cases of thrombosis with thrombocytopenia syndrome (TTS) reported after receiving the vaccine. TTS can cause dangerous blood clots.

Subscribe to The Week

Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.

SUBSCRIBE & SAVE
https://cdn.mos.cms.futurecdn.net/flexiimages/jacafc5zvs1692883516.jpg

Sign up for The Week's Free Newsletters

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.

Sign up
To continue reading this article...
Continue reading this article and get limited website access each month.
Get unlimited website access, exclusive newsletters plus much more.
Cancel or pause at any time.
Already a subscriber to The Week?
Not sure which email you used for your subscription? Contact us